135 results on '"Lima EG"'
Search Results
2. Cost-Effectiveness Analysis of On-Pump and Off-Pump Stable Multivessel Coronary Artery Bypass Grafting–mass iii 5-Year Follow-Up
- Author
-
Scudeler, TL, primary, Hueb, W, additional, de Soárez, PC, additional, Campolina, AG, additional, Hueb, AC, additional, Rezende, PC, additional, Lima, EG, additional, Garzillo, CL, additional, Costa, LM, additional, Oikawa, FT, additional, Ramires, JA, additional, and Kalil Filho, R, additional
- Published
- 2016
- Full Text
- View/download PDF
3. Estudo da Qualidade das Águas Adicionadas de Sais Produzidas no Estado Do Ceará
- Author
-
COSTA, MTP, primary, MORAIS, EP, additional, PASSOS, MAR, additional, LIMA, EG, additional, SILVA, LMR, additional, BORGES, MF, additional, and FIGUEIREDO, EAT, additional
- Published
- 2015
- Full Text
- View/download PDF
4. Bonding of Y-TZP to Dentin: Effects of Y-TZP Surface Conditioning, Resin Cement Type, and Aging
- Author
-
Bottino, MA, primary, Bergoli, C, primary, Lima, EG, primary, Marocho, SMS, primary, Souza, RO, primary, and Valandro, LF, primary
- Published
- 2014
- Full Text
- View/download PDF
5. I Diretriz sobre Aspectos Específicos de Diabetes (tipo 2) Relacionados à Cardiologia
- Author
-
Gualandro, DM, primary, Azevedo, FR, additional, Calderaro, D, additional, Marcondes-Braga, FG, additional, Caramelli, B, additional, Schaan, BD, additional, Soeiro, AM, additional, Mansur, AP, additional, Rochitte, CE, additional, Serrano Jr., CV, additional, Garzillo, CL, additional, Lima, EG, additional, Lima, FG, additional, Oliveira, FM, additional, Chauhan, H, additional, Salles, JEN, additional, Soares Jr., J, additional, Cardoso, JN, additional, Pellanda, LC, additional, Sacilotto, L, additional, Baracioli, L, additional, Bortolotto, LA, additional, César, LAM, additional, Ochiai, ME, additional, Minami, MH, additional, Pinheiro, MB, additional, Moretti, MA, additional, Oliveira, MT, additional, Rezende, PC, additional, Lemos Neto, PA, additional, Admoni, SN, additional, Lottenberg, SA, additional, Rocha, VZ, additional, Hueb, W, additional, and Mathias Jr., W, additional
- Published
- 2014
- Full Text
- View/download PDF
6. PCV93 - Cost-Effectiveness Analysis of On-Pump and Off-Pump Stable Multivessel Coronary Artery Bypass Grafting–mass iii 5-Year Follow-Up
- Author
-
Scudeler, TL, Hueb, W, de Soárez, PC, Campolina, AG, Hueb, AC, Rezende, PC, Lima, EG, Garzillo, CL, Costa, LM, Oikawa, FT, Ramires, JA, and Kalil Filho, R
- Published
- 2016
- Full Text
- View/download PDF
7. Cancer-related deaths among different treatment options in chronic coronary artery disease: results of a 6-year follow-up of the MASS II study.
- Author
-
Vieira RD, Pereira AC, Lima EG, Garzillo CL, Rezende PC, Favarato D, Hueb AC, Gersh BJ, Ramires JA, and Hueb W
- Published
- 2012
- Full Text
- View/download PDF
8. Abnormal neurovascular control during sympathoexcitation in obesity
- Author
-
Kuniyoshi, Fs, Tombetta, Ic, Batalha, Lt, Rondon, Mupb, Laterza, Mc, Gowdak, Mmg, Barretto, Acp, Halpern, A., Sandra Mara Villares, Lima, Eg, and Negrao, Ce
9. Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease: MASS II Trial.
- Author
-
Vieira RD, Hueb W, Gersh BJ, Lima EG, Pereira AC, Rezende PC, Garzillo CL, Hueb AC, Favarato D, Soares PR, Ramires JA, and Filho RK
- Published
- 2012
- Full Text
- View/download PDF
10. Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease: 5-Year Follow-Up of Medicine, Angioplasty, or Surgery Study (MASS) II Trial.
- Author
-
Vieira RD, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL, Lima EG, Soares PR, Hueb AC, Pereira AC, Ramires JA, and Filho RK
- Published
- 2012
- Full Text
- View/download PDF
11. Effect of cementation protocols on the fracture load of bilayer ceramic crowns manufactured by the Rapid Layer Technology.
- Author
-
Silva SEGD, Lima JMC, Lima EG, Melo RM, Bottino MA, and Souza ROAE
- Subjects
- Zirconium chemistry, Dental Restoration Failure, Dental Cements chemistry, Ceramics chemistry, Crowns, Dental Stress Analysis, Materials Testing, Cementation methods
- Abstract
To evaluate the fracture load of bilayer ceramic crowns manufactured by Rapid Layer Technology (RLT) after different cementation protocols of the veneering ceramic to the zirconia infrastructures. Sixty epoxy resin preparations simulating a molar tooth were obtained and 60 zirconia infrastructures and feldspathic crowns were manufactured by RLT and divided into 6 groups according to the cementation protocol at the interface to veneering ceramic (n=10): Ctr- control: conventional resin cement; Al- Al2O3 sandblasting 50µm + conventional resin cement; Al/MDP- Al2O3 sandblasting (50µm) + resin cement with MDP; Sil- silicatization 30µm + conventional resin cement; Gl/HF- glaze + hydrofluoridric acid (5%,60s) + silane + conventional resin cement; Gl- glazing as bonding agent. The feldspathic ceramic internal surface was etched with fluoridric acid (5%) + silane followed by cementation according to respective protocols. All samples were mechanically cycled (200N and 4.5x105 Pa, 37°C, 2x106 cycles, 3.4Hz) and submitted to axial compressing fracture load test (10kN, 0.5mm/min). The results(N) were submitted to descriptive and analytical statistical analysis with 1-way ANOVA, Weibull, and the Tukey test (α=0.05). ANOVA revealed that there was a significant difference among the tested groups (p<0.0001). The group Al/MDP presented the higher resistance to fracture (1972.46A N), followed by the Ctr group (1584.41B N). The characteristic strength(σ0) was significantly different (p=0.000). The crack and chipping were the predominant failures. The air-abrasion at the external surface of zirconia with Al2O3 followed by cementation with MDP resin cement, should be selected to Rapid Layer Technique when felspathic ceramic is used as veneer ceramic.
- Published
- 2024
- Full Text
- View/download PDF
12. Quality Control in RT-PCR Viral Load Assays: Evaluation of Analytical Performance for HIV, HBV, and HCV.
- Author
-
Gomes GTA, Lima EG, de Oliveira Dos Santos VT, Araújo LMSB, and Porto GMR
- Abstract
Introduction: Quality Control Management (QCM) in clinical laboratories is crucial for ensuring reliable results in analytical measurements, with biological variation being a key factor. The study focuses on assessing the analytical performance of the Reverse Transcription Polymerase Chain Reaction (RT-PCR) system for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), and Hepatitis C (HCV). Five models proposed between 1999 and 2014 offer different approaches to evaluating analytical quality, with Model 2 based on biological variation and Model 5 considering the current state of the art. The study evaluates the RT-PCR system's analytical performance through Internal Quality Control (IQC) and External Quality Control (EQC)., Materials and Methods: The Laboratório Central de Saúde Pública do Estado do Ceará (LACEN-CE) conducted daily IQC using commercial kits, and EQC was performed through proficiency testing rounds. Random error, systematic error, and total error were determined for each analyte., Results: Analytical performance, assessed through CV and random error, met specifications, with HIV and HBV classified as "desirable" and "optimal." EQC results indicated low systematic error, contributing to total errors considered clinically insignificant., Conclusion: The study highlights the challenge of defining analytical specifications without sufficient biological variability data. Model 5 is deemed the most suitable. The analytical performance of the RT-PCR system for HIV, HBV, and HCV at LACEN-CE demonstrated satisfactory, emphasizing the importance of continuous quality control in molecular biology methodologies., (Copyright © 2024 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved.)
- Published
- 2024
13. Electronic Glycemic Management System Improved Glycemic Control and Reduced Complications in Patients With Diabetes Undergoing Coronary Artery Bypass Surgery: A Randomized Controlled Trial.
- Author
-
Câmara de Souza AB, Toyoshima MTK, Cukier P, Lottenberg SA, Bolta PMP, Lima EG, Serrano Júnior CV, and Nery M
- Abstract
Background: In-hospital hyperglycemia poses significant risks for patients with diabetes mellitus undergoing coronary artery bypass graft (CABG) surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP offer promise in standardizing and improving glycemic control (GC) in these settings. This study evaluated the efficacy of the InsulinAPP protocol in optimizing GC and reducing adverse outcomes post-CABG., Methods: This prospective, randomized, open-label study was conducted with 100 adult type 2 diabetes mellitus (T2DM) patients post-CABG surgery, who were randomized into two groups: conventional care (gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin therapy management, whereas the gCONV received standard clinical care. The primary outcome was a composite of hospital-acquired infections, renal function deterioration, and symptomatic atrial arrhythmia. Secondary outcomes included GC, hypoglycemia incidence, hospital stay length, and costs., Results: The gAPP achieved lower mean glucose levels (167.2 ± 42.5 mg/dL vs 188.7 ± 54.4 mg/dL; P = .040) and fewer patients-day with BG above 180 mg/dL (51.3% vs 74.8%, P = .011). The gAPP received an insulin regimen that included more prandial bolus and correction insulin (either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs 16.7%). The primary composite outcome occurred in 16% of gAPP patients compared with 58% in gCONV ( P < .010). Hypoglycemia incidence was lower in the gAPP (4% vs 16%, P = .046). The gAPP protocol also resulted in shorter hospital stays and reduced costs., Conclusions: The InsulinAPP protocol effectively optimizes GC and reduces adverse outcomes in T2DM patients' post-CABG surgery, offering a cost-effective solution for inpatient diabetes management., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
14. Angina Pectoris and Orbita 2 Trial: Reflections on the Future of Angina Treatment.
- Author
-
Martins EB, Lima EG, Linhares Filho JPP, Pinesi HT, Pitta FG, and Serrano Júnior CV
- Subjects
- Humans, Randomized Controlled Trials as Topic, Clinical Trials as Topic, Angina Pectoris therapy
- Published
- 2024
- Full Text
- View/download PDF
15. Unveiling myocardial microstructure shifts: exploring the impact of diabetes in stable CAD patients through CMR T1 mapping.
- Author
-
Boros GAB, Hueb W, Rezende PC, Rochitte CE, Nomura CH, Lima EG, de Oliveira Laterza Ribeiro M, Dallazen AR, Garcia RMR, Ramires JAF, and Kalil-Filho R
- Abstract
Background: This study investigates myocardial structural changes in stable coronary artery disease (CAD) patients with type 2 diabetes (T2D) using cardiac magnetic resonance (CMR) strain and T1 mapping., Methods: A total of 155 stable CAD patients underwent CMR examination, including left ventricular (LV) morphology and function assessment, late gadolinium enhancement (LGE), and feature tracking (CMR-FT) for LV global longitudinal, circumferential, and radial strain. T1 mapping with extracellular volume (ECV) evaluation was also performed., Results: Among the enrolled patients, 67 had T2D. Diabetic patients exhibited impaired LV strain and higher ECV compared to non-diabetics. Multivariate analysis identified T2D as an independent predictor of increased ECV and decreased strain., Conclusions: CMR-based strain and T1 mapping highlighted impaired myocardial contractility, elevated ECV, and potential interstitial fibrosis in diabetic patients with stable CAD. This suggests a significant impact of diabetes on myocardial health beyond CAD, emphasizing the importance of a comprehensive assessment in these individuals., Trial Registration: http://www.controlled-trials.com/ISRCTN09454308., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. Association between obstructive coronary disease and diabetic retinopathy: Cross-sectional study of coronary angiotomography and multimodal retinal imaging.
- Author
-
Campos AC, Lima EG, Jacobsen PK, Arnould L, Lottenberg S, Maia RM, Conci LS, Minelli T, Morato A, Dantas-Jr RN, Nomura CH, Rissoli P, Pimentel SG, and Serrano Junior CV
- Subjects
- Male, Humans, Female, Cross-Sectional Studies, Single-Blind Method, Retinal Vessels diagnostic imaging, Tomography, Optical Coherence methods, Diabetic Retinopathy diagnosis, Diabetic Retinopathy diagnostic imaging, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease epidemiology, Insulins, Diabetes Mellitus
- Abstract
Aims: To investigate the association between diabetic retinopathy (DR) and coronary artery disease (CAD) using coronary angiotomography (CCTA) and multimodal retinal imaging (MMRI) with ultra-widefield retinography and optical coherence tomography angiography and structural domain., Methods: Single-center, cross-sectional, single-blind. Patients with diabetes who had undergone CCTA underwent MMRI. Uni and multivariate analysis were used to assess the association between CAD and DR and to identify variables independently associated with DR., Results: We included 171 patients, 87 CAD and 84 non-CAD. Most CAD patients were males (74 % vs 38 %, P < 0.01), insulin users (52 % vs 38 %, p < 0.01) and revascularized (64 %). They had a higher prevalence of DR (48 % vs 22 %, p = 0.01), microaneurysms (25 % vs 13 %, p = 0.04), intraretinal cysts (22 % vs 8 %, p = 0.01) and areas of reduced capillary density (46 % vs 20 %, p < 0.01). CAD patients also had lower mean vascular density (MVD) (15.7 % vs 16.5,%, p = 0.049) and foveal avascular zone (FAZ) circularity (0.64 ± 0.1 vs 0.69 ± 0.1, p = 0.04). There were significant and negative correlations between Duke coronary score and MVD (r = -0.189; p = 0.03) and FAZ circularity (r = -0,206; p = 0.02). CAD, DM duration and insulin use independently associated with DR., Conclusions: CAD patients had higher prevalence of DR and lower MVD. CAD, DM duration and insulin use were independently associated with DR., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Primary results of the brazilian registry of atherothrombotic disease (NEAT).
- Author
-
de Barros E Silva PGM, do Nascimento CT, Pedrosa RP, Nakazone MA, do Nascimento MU, de Araújo Melo L, Júnior OLS, Zimmermann SL, de Melo RMV, Bergo RR, Precoma DB, Tramujas L, Lima EG, Dantas JMM, do Amaral Baruzzi AC, Flumignan RLG, de Oliveira Paiva MSM, Gowdak LHW, de Carvalho PN, de Figueiredo Neto JA, Silvestre OM, Fioranelli A, Vieira RD', Horak ACP, Miyada DHK, Kojima FCS, de Oliveira JS, de Oliveira Silva L, Pavanello R, Ramacciotti E, and Lopes RD
- Subjects
- Aged, Female, Humans, Male, Brazil epidemiology, Prospective Studies, Registries, Risk Factors, Rivaroxaban therapeutic use, Middle Aged, Multicenter Studies as Topic, Observational Studies as Topic, Coronary Artery Disease drug therapy, Peripheral Arterial Disease epidemiology
- Abstract
There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of patients with known coronary (CAD) and/or peripheral arterial disease (PAD) in Brazil. A total of 2,005 patients were enrolled among 25 sites from September 2020 to March 2022. Patient characteristics, medications and laboratorial data were collected. Primary objective was to assess the proportion of patients who, at the initial visit, were in accordance with good medical practices (domains) for reducing cardiovascular risk in atherothrombotic disease. From the total of patients enrolled, 2 were excluded since they did not meet eligibility criteria. Among the 2,003 subjects included in the analysis, 55.6% had isolated CAD, 28.7% exclusive PAD and 15.7% had both diagnoses. Overall mean age was 66.3 (± 10.5) years and 65.7% were male patients. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5 mg bid). Only 0.3% of the patients satisfied all the domains of secondary prevention, including prescription of EBTs and targets of body-mass index, blood pressure, LDL-cholesterol, and adherence of lifestyle recommendations. The main barrier for prescription of EBTs was medical judgement. Our findings highlight that the contemporary practice does not reflect a comprehensive approach for secondary prevention and had very low incorporation of new therapies in Brazil. Large-scale populational interventions addressing these gaps are warranted to improve the use of evidence-based therapies and reduce the burden of atherothrombotic disease.ClinicalTrials.gov NCT04677725., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Abnormal release of cardiac biomarkers in the presence of myocardial oedema evaluated by cardiac magnetic resonance after uncomplicated revascularization procedures.
- Author
-
Ribas FF, Hueb W, Rezende PC, Rochitte CE, Nomura CH, Villa AV, Morais TC, Lima EG, Boeing Boros GA, Ribeiro MOL, Linhares-Filho JPP, Dallazen AR, Silva RRM, Franchini Ramires JA, and Kalil-Filho R
- Subjects
- Humans, Stroke Volume, Gadolinium, Magnetic Resonance Imaging, Biomarkers, Creatine Kinase, MB Form, Edema, Magnetic Resonance Spectroscopy, Contrast Media, Ventricular Function, Left
- Abstract
Aims: To analyse the association of myocardial oedema (ME), observed as high T2 signal intensity (HT2) in cardiac magnetic resonance imaging, with the release of cardiac biomarkers, ventricular ejection, and clinical outcomes after revascularization., Methods and Results: Patients with stable coronary artery disease with the indication for revascularization were included. Biomarker levels [troponin I (cTnI) and creatine kinase MB (CK-MB)] and T2-weighted and late gadolinium enhancement (LGE) images were obtained before and after the percutaneous or surgical revascularization procedures. The association of HT2 with the levels of biomarkers, with and without LGE, evolution of left ventricular ejection fraction (LVEF), and 5-year clinical outcomes were assessed. A total of 196 patients were divided into 2 groups: Group 1 (HT2, 40) and Group 2 (no HT2, 156). Both peak cTnI (8.9 and 1.6 ng/mL) and peak CK-MB values (44.7 and 12.1 ng/mL) were significantly higher in Group 1. Based on the presence of new LGE, patients were stratified into Groups A (no HT2/LGE, 149), B (HT2, 9), C (LGE, 7), and D (both HT2/LGE, 31). The peak cTnI and CK-MB values were 1.5 and 12.0, 5.4 and 44.7, 5.0 and 18.3, and 9.8 and 42.8 ng/mL in Groups A, B, C, and D, respectively, and were significantly different. The average LVEF decreased by 4.4% in Group 1 and increased by 2.2% in Group 2 (P = 0.057)., Conclusion: ME after revascularization procedures was associated with increased release of cardiac necrosis biomarkers, and a trend towards a difference in LVEF, indicating a role of ME in cardiac injury after interventions., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
19. Two-Year Follow-Up of Chronic Ischemic Heart Disease Patients in a Specialized Center in Brazil.
- Author
-
Moreira EM, Pinesi HT, Martins EB, Pitta FG, Bolta PMP, Segre CAW, Favarato D, Rached FH, Hueb WA, Lima EG, Kalil Filho R, Garzillo CL, and Serrano CV Jr
- Subjects
- Humans, Female, Aged, Male, Follow-Up Studies, Brazil epidemiology, Canada, Cholesterol, LDL, Myocardial Ischemia epidemiology, Myocardial Infarction, Stroke epidemiology
- Abstract
The incidence of cardiovascular events in patients with chronic ischemic heart disease (CIHD) may vary significantly among countries. Although populous, Brazil is often underrepresented in international records. This study aimed to describe the quality of care and the two-year incidence of cardiovascular events and associated prognostic factors in CIHD patients in a tertiary public health care center in Brazil. Patients with CIHD who reported for clinical evaluation at Instituto do Coração (São Paulo, Brazil) were registered and followed for two years. The primary endpoint was a composite of myocardial infarction (MI), stroke, or death. A significance level of 0.05 was adopted. From January 2016 to December 2018, 625 participants were included in the study. Baseline characteristics show that 33.1% were women, median age 66.1 [59.6 - 71.9], 48.6% had diabetes, 83.1% had hypertension, 62.6% had previous MI, and 70.4% went through some revascularization procedure. At a median follow-up (FU) of 881 days, we noted 37 (7.05%) primary endpoints. After adjustments, age, previous stroke, and LDL-cholesterol were independently associated with the primary endpoint. Comparing baseline versus FU, participants experienced relief of angina based on the Canadian Cardiovascular Society (CCS) scale according to the following percentages: 65.7% vs. 81.7% were asymptomatic and 4.2% vs. 2.9% CCS 3 or 4 (p < 0.001). They also experienced better quality of medication prescription: 65.8% vs. 73.6% (p < 0.001). However, there was no improvement in LDL-cholesterol or blood pressure control. This study shows that CIHD patients had a two-year incidence of the primary composite endpoint of 7.05%, and the reduction of LDL-cholesterol was the only modifiable risk factor associated with prognosis.
- Published
- 2023
- Full Text
- View/download PDF
20. Myocardial tissue microstructure with and without stress-induced ischemia assessed by T1 mapping in patients with stable coronary artery disease.
- Author
-
de Oliveira Laterza Ribeiro M, Hueb W, Rezende PC, Lima EG, Nomura CH, Rochitte CE, da Silva Selistre L, Boros GAB, Ramires JAF, and Filho RK
- Subjects
- Humans, Prospective Studies, Magnetic Resonance Imaging, Cine methods, Predictive Value of Tests, Myocardium pathology, Ischemia pathology, Contrast Media, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease pathology, Percutaneous Coronary Intervention, Myocardial Ischemia complications, Myocardial Ischemia diagnostic imaging
- Abstract
Background: Stress-induced myocardial ischemia seems not to be associated with cardiovascular events. However, its effects on myocardial tissue characteristics remain under debate. Thus, we sought to assess whether documented stress-induced ischemia is associated with changes in myocardial microstructure evaluated by magnetic resonance native T1 map and extracellular volume fraction (ECV)., Methods: This is a single-center, analysis of the previously published MASS V Trial. Multivessel patients with a formal indication for myocardial revascularization and with documented stress-induced ischemia were included in this study. Native T1 and ECV values evaluated by cardiac magnetic resonance imaging of ischemic and nonischemic myocardial segments at rest and after stress were compared. Myocardial ischemia was detected by either nuclear scintigraphy or stress magnetic cardiac resonance protocol., Results: Between May 2012 and March 2014, 326 prospective patients were eligible for isolated CABG or PCI and 219 were included in the MASS V trial. All patients underwent resting cardiac magnetic resonance imaging. Of a total of 840 myocardial segments, 654 were nonischemic segments and 186 were ischemic segments. Native T1 and ECV values of ischemic segments were not significantly different from nonischemic segments, both at rest and after stress induction. In addition, native T1 and ECV values of myocardial segments supplied by vessels with obstructive lesions were similar to those supplied by nonobstructive ones., Conclusion and Relevance: In this study, cardiac magnetic resonance identified similar T1 mapping values between ischemic and nonischemic myocardial segments. This finding suggests integrity and stability of myocardial tissue in the presence of stress-induced ischemia., Competing Interests: Declaration of competing interest All authors have no conflicts of interest to disclose., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
21. Coronavirus disease-2019 and heart: assessment of troponin and cardiovascular comorbidities as prognostic markers in patients hospitalized with coronavirus disease-2019 in a tertiary center in Brazil.
- Author
-
Pinesi HT, Giugni FR, Matuck BRS, Pitta FG, Garzillo CL, Lima EG, Kalil Filho R, and Serrano Junior CV
- Subjects
- Humans, Troponin, Brazil epidemiology, Troponin T, Prognosis, Biomarkers, COVID-19, Coronavirus
- Abstract
Objective: Our study aimed to evaluate the correlation of cardiac troponin T levels with comorbidities and in-hospital outcomes in patients with coronavirus disease-2019 in Brazil., Methods: Data from a cohort of 3,596 patients who were admitted with suspected coronavirus disease-2019 in a Brazilian tertiary center, between March and August 2020, were reviewed. A total of 2,441 (68%) patients had cardiac troponin T determined in the first 72 h of admission and were stratified into two groups: elevated cardiac troponin T (cardiac troponin T >0.014 ng/mL) and normal cardiac troponin T. Associations between troponin, comorbidities, biomarkers, and outcomes were assessed. Regression models were built to assess the association of several variables with in-hospital mortality., Results: A total of 2,441 patients were embraced, of which 924 (38%) had normal cardiac troponin T and 1,517 (62%) had elevated cardiac troponin T. Patients with elevated cardiac troponin T were older and had more comorbidities, such as cardiovascular disease, hypertension, diabetes, arrhythmia, renal dysfunction, liver disease, stroke, cancer, and dementia. Patients with abnormal cardiac troponin T also had more altered laboratory parameters on admission (i.e., leukocytes, C-reactive protein, D-dimer, and B-type natriuretic peptide), as well as more need for intensive care unit, vasoactive drugs, mechanical ventilation, dialysis, and blood transfusion. All-cause mortality was markedly higher among patients with increased cardiac troponin T (42 vs. 16%, P<0.001). Multiple regression analysis demonstrated that in-hospital mortality was not independently associated with troponin elevation., Conclusion: This study showed that cardiac troponin T elevation at admission was common and associated with several comorbidities, biomarkers, and clinical outcomes in patients hospitalized with coronavirus disease-2019, but it was not an independent marker of in-hospital mortality.
- Published
- 2023
- Full Text
- View/download PDF
22. The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study.
- Author
-
Feitosa MPM, Lima EG, Abizaid AAC, Mehran R, Lopes NHM, de Assis Fischer Ramos T, Hideo-Kajita A, Filho RK, and Junior CVS
- Abstract
Background: Percutaneous coronary intervention (PCI) is one of the most performed well-succeeded therapeutic procedures worldwide, reducing symptoms and improving quality of life. Neutrophil Gelatinase-associated Lipocalin (NGAL) is a biomarker of acute kidney injury (AKI) produced early after an ischemic renal insult. Osmotic diuresis and the vasoconstriction of the afferent arteriole promoted by Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) generate a concern regarding the possibility of dehydration and consequent AKI. There is no consensus on the maintenance or discontinuation of SGTL2i in patients who will undergo PCI. This study aimed to evaluate the safety of empagliflozin in diabetic patients submitted to elective PCI regarding kidney function., Methods: SAFE-PCI trial is a prospective, open-label, randomized (1:1), single-center pilot study and a follow-up of 30 days. The SGLT2i empagliflozin 25 mg daily was initiated at least 15 days before PCI in the intervention group and maintained until the end of the follow-up period. Serum NGAL was collected 6 h after PCI and creatinine before PCI, 24 h, and 48 h after the procedure. As per protocol, both groups received optimal medical treatment and standard protocol of nephroprotection., Results: A total of 42 patients were randomized (22 patients in the iSGLT-2 group and 20 patients in the control group). There was no difference between-group baseline data. The primary outcome (NGAL and creatinine values post PCI) did not differ in both groups: the mean NGAL value was 199 ng/dL in the empagliflozin group and 150 ng/dL in the control group (p = 0.249). Although there was an initial increase in creatinine in the SGLT-2i group compared to the control group between baseline creatinine and pre-PCI and 24 h post-PCI creatinine, no difference was detected in creatinine 48 h post-PCI (p = 0.065). The incidence of CI-AKI, determined by KDIGO criteria, in the iSGLT2-group was 13.6% and 10.0% in the control group without statistical difference., Conclusion: The present study showed that the use of empagliflozin is safe regarding kidney function during elective PCI in patients with T2D when compared with no use of SGLT2i. Trial registration Our clinical study is registered on ClinicalTrials.gov with the following number: NCT05037695., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
23. Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial.
- Author
-
Pereira MP, Lima EG, Pitta FG, Gowdak LHW, Mioto BM, Carvalho LNS, Darrieux FCDC, Mejia OAV, Jatene FB, and Serrano CV Jr
- Abstract
Objectives: Postoperative atrial fibrillation is the most common clinical complication after coronary artery bypass graft surgery. It is associated with a high risk of both stroke and death and increases the length of hospital stay and costs. This study aimed to evaluate anticoagulants in postoperative atrial fibrillation., Methods: A single-center, randomized, prospective, and open-label study. The trial was conducted in Heart Institute at University of São Paulo, Brazil. Patients who developed postoperative atrial fibrillation were randomized to anticoagulation with rivaroxaban or warfarin plus enoxaparin bridging. The primary objective was the cost-effectiveness evaluated by quality-adjusted life years, using the SF-6D questionnaire. The secondary end point was the combination of death, stroke, myocardial infarction, thromboembolic events, infections, bleeding, readmissions, and surgical reinterventions. The safety end point was any bleeding using the International Society on Thrombosis and Haemostasis score. Follow-up period was 30 days after hospital discharge., Results: We analyzed 324 patients and 53 patients were randomized. The median cost-effectiveness was $1423.20 in the warfarin group versus $586.80 in the rivaroxaban group ( P = .002). The median cost was lower in the rivaroxaban group, $450.20 versus $947.30 ( P < .001). The secondary outcome was similar in both groups, 44.4% in warfarin group versus 38.5% in the rivaroxaban group ( P = .65). Bleeding occured in 25.9% in the warfarin group versus 11.5% in the rivaroxaban group ( P = .18)., Conclusions: Rivaroxaban was more cost-effective when compared with warfarin associated with enoxaparin bridging in postoperative atrial fibrillation after isolated coronary artery bypass grafting., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. The Brazilian Portuguese version of the Pregnancy Mobility Index: Cross-cultural adaptation and psychometric evaluation - a validation study.
- Author
-
Feltrin MI, Gallo RBS, Lima EG, Bertoncini NHG, Silva JBD, Moreira NB, and Korelo RIG
- Subjects
- Pregnancy, Humans, Female, Brazil, Psychometrics, Reproducibility of Results, Cross-Cultural Comparison, Pain
- Abstract
Background: The Pregnancy Mobility Index (PMI) was developed to assess mobility in pregnant women in the Netherlands. At present, no similar questionnaire is available in Brazil., Objective: The present study aimed to translate, cross-culturally adapt, and evaluate the psychometric properties of a Brazilian PMI., Design and Setting: The present study was a validation study conducted at the Universidade Federal do Paraná and a public maternity ward in Curitiba, Brazil., Methods: Text translation and cross-cultural adaptation followed international guidelines. Construct validity, internal consistency, and inter- and intra-rater reliability tests included 97 women. The Pelvic Girdle Questionnaire, Multidimensional Pain Evaluation Scale, Schober's test, and lumbar spine range of motion assessment were administered on the first day. Intra-rater reliability (n = 19) was measured after 15 days. Exploratory factor analysis was performed, and the correlation matrix was analyzed using Pearson's coefficient., Results: Pregnant women (88%) understood the cultural adaptation process. The internal consistency was high (Cronbach's alpha > 0.90), construct validity was moderate, with significant correlation between lumbar spine range of motion (r = 0.283-0.369) and Schober's test (r = -0.314), and high correlation between the Multidimensional Pain Evaluation Scale (r = -0.650 and -0.499) and Pelvic Girdle Questionnaire (r = -0.737). Intra- and inter-rater reliabilities were excellent (intraclass correlation coefficient = 0.932 and 0.990, respectively)., Conclusion: The Brazilian version of the PMI was successfully translated with excellent reliability and moderate-to-high construct validity. It is an important tool for assessing mobility in pregnant women., Clinical Trial: RBR-789tps (Validation study), https://ensaiosclinicos.gov.br/rg/RBR-789tps.
- Published
- 2023
- Full Text
- View/download PDF
25. Cardiovascular events in patients with coronary artery disease with and without myocardial ischemia: Long-term follow-up.
- Author
-
Carvalho FPC, Hueb W, Lima EG, Rezende PC, Linhares Filho JPP, Garcia RMR, Soares PR, Ramires JAF, and Kalil Filho R
- Subjects
- Humans, Follow-Up Studies, Retrospective Studies, Prognosis, Risk Factors, Coronary Artery Disease, Myocardial Ischemia complications, Myocardial Ischemia epidemiology, Myocardial Infarction complications
- Abstract
Background: After the results of the ISCHEMIA Trial, the role of myocardial ischemia in the prognosis of coronary artery disease (CAD) was under debate. We sought to comparatively evaluate the long-term prognosis of patients with multivessel CAD with or without documented myocardial ischemia., Methods: This is a single-center, retrospective, observational cohort study that included patients with CAD obtained from the research protocols database of "The Medicine, Angioplasty or Surgery Study," the MASS Study Group. Patients were stratified according to the presence or absence of myocardial ischemia. Cardiovascular events (overall mortality and myocardial infarction) were tracked from the registry entry up to a median follow-up of 8.7 years. Myocardial ischemia was assessed at baseline by a functional test with or without imaging., Results: From 1995 to 2018, 2015 patients with multivessel CAD were included. Of these, 1001 presented with conclusive tests at registry entry, 790 (79%) presenting with ischemia and 211 (21%) without ischemia. The median follow-up was 8.7 years (IQR 4.04 to 10.07). The primary outcome occurred in 228 (28.9%) patients with ischemia and in 64 (30.3%) patients without ischemia (p
log-rank =0.60). No significant interaction was observed with the presence of myocardial ischemia and treatment strategies in the occurrence of the combined primary outcome (pinteration =0.14)., Conclusions: In this sample, myocardial ischemia was not associated with a worse prognosis compared with no ischemia in patients with multivessel CAD. These results refer to debates about the role of myocardial ischemia in the occurrence of cardiovascular events., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
26. Long-term analysis of ventricular function in patients with symptomatic coronary disease who underwent on-pump or off-pump coronary artery bypass grafting.
- Author
-
Silva RRM, Hueb W, Lima EG, Rezende PC, Soares PR, Ramires JAF, and Filho RK
- Subjects
- Humans, Prospective Studies, Treatment Outcome, Coronary Artery Bypass methods, Ventricular Function, Left, Coronary Artery Disease surgery
- Abstract
Background: Systemic deleterious effects of cardiopulmonary bypass have been observed in the postprocedural period. Long-term assessment, including ventricular function (VF), is unclear. The objective of this study was to compare the change of left ventricular ejection fractions (LVEFs) during a long-term follow-up of coronary artery disease (CAD) patients who underwent off-pump (OPCAB) or on-pump coronary artery bypass grafting (ONCAB)., Methods: This study is a prespecified analysis of the MASS III trial, which was a single-center and prospective study that enrolled stable CAD patients with preserved VF. The CAD patients in our study were randomized to OPCAB or ONCAB. A transthoracic echocardiogram was performed during follow-up and a LVEF value was obtained. The primary endpoint was the difference between the final LVEF and the baseline LVEF., Results: Of the 308 randomized patients, ventricular function were observed in 225 over a mean of 5.9 years of follow-up: 113 in the ONCAB group and 112 in the OPCAB group. Baseline characteristics were similar between the two groups, but there was a larger proportion of subjects with 3-vessel disease in the ONCAB group. There was no difference in the LVEF at the beginning (P = 0.08), but there was a slight decrease in the LVEF in the ONCAB and OPCAB groups (P < 0.001 in both groups) at 5.9 years. The decline was not significantly different between the two groups (delta of -6% for ONCAB and -5% for OPCAB; P = 0.78). In a multivariate analysis, myocardial infarction in the follow-up was a predictor of an LVEF < 40%., Conclusions: There was no difference in the long-term development of ventricular function between the surgical techniques, despite a decline in the LVEF in both groups. Trial registration Clinical Trial Registration Information-URL: http://www.controlled-trials.com ., Registration Number: ISRCTN59539154. Date of first registration: 10/03/2008., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
27. Evaluation of cardiovascular risk biomarkers after moderate consumption of red wine and cachaça in a randomized crossover trial: The Wine and Cachaça Study (WICAS).
- Author
-
Henrique de Moraes Cellia P, Lima EG, Agrizzi de Angeli LR, Martins EB, Rached FH, Pitta FG, Cassaro Strunz CM, and Serrano CV Jr
- Subjects
- Male, Female, Humans, Adult, Middle Aged, Cross-Over Studies, Prospective Studies, Risk Factors, Biomarkers, Heart Disease Risk Factors, Weight Gain, Wine analysis, Cardiovascular Diseases
- Abstract
Introduction: Moderate daily consumption of alcohol (MDCA) is associated with cardiovascular risk (CVR) reduction in observational studies. Some researches have suggested that this benefit may be associated not only with red wine consumption but also with other beverages. However, there are no clinical trials evaluating the possible CVR benefit of Brazilian spirit (cachaça) in humans., Methods: This is a prospective, randomized, crossover study including healthy individuals initially assigned to a MDCA of cachaça or red wine for a period of 4 weeks. After a one-week abstinence period, the type of drink was changed for another 4 weeks of intervention. The MDCA for both beverages was determined as a dose equivalent to 28 g of ethanol per day for men and 14 g for women. CVR biomarkers analyses were performed before and after each intervention to assess the serologic status of C-reactive protein, lipid profile, platelet aggregation and glycemic profile. This study is registered on the ISRCTN platform under number 15978506., Results: Of the 42 subjects initially randomized, 2 refused to continue in the study. The median age was 44.3 ± 10.3 years and 19 were male (47.5%). Adherence to the protocol was considered ideal with 100% regular use in both interventions and only 3 individuals in each intervention group reported alcohol abuse. There was no significant variation in anthropometric measurements during the study, except for weight gain (0.7 kg) in the red wine group (p = 0.005). The median of the delta of platelet aggregation for MDCA of cachaça was 1.2% (-1.1 to 5.3) and the median of the delta to the MDCA of wine was -1.6% (-4.5 to 2) (p = 0.02). The other biomarkers didn't show any statistically significant variation., Conclusion: Moderate consumption of wine and cachaça was related to variation in laboratory biomarkers of CVR related to atherosclerosis. There was significant weight gain during the period of wine consumption and there was observed a difference between platelet aggregation values after both interventions., Competing Interests: Declaration of competing interest Pedro Henrique de Moraes Cellia is the son of the owner of the company that provided the cachaça samples for the study. The others authors indicate no conflict of interest., (Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
28. Quality improvement program in Latin America decreases mortality after cardiac surgery: a before-after intervention study.
- Author
-
Mejia OAV, Borgomoni GB, Palma Dallan LR, Mioto BM, Duenhas Accorsi TA, Lima EG, de Matos Soeiro A, Lima FG, Manuel de Almeida Brandão C, Alberto Pomerantzeff PM, Oliveira Dallan LA, Ferreira Lisboa LA, and Jatene FB
- Subjects
- Humans, Quality Improvement, Latin America epidemiology, Coronary Artery Bypass methods, Hospital Mortality, Treatment Outcome, Retrospective Studies, Postoperative Complications, Cardiac Surgical Procedures adverse effects, Thoracic Surgery
- Abstract
Background: The current challenge of cardiac surgery (CS) is to improve outcomes in adverse scenarios. The aim of this study was to assess the impact of a quality improvement program (QIP) on hospital mortality in the largest CS center in Latin America., Methods: Patients were divided into two groups: before (Jan 2013-Dec 2015, n = 3534) and after establishment of the QIP (Jan 2017-Dec 2019, n = 3544). The QIP consisted of the implementation of 10 central initiatives during 2016. The procedures evaluated were isolated coronary artery bypass grafting surgery (CABG), mitral valve surgery, aortic valve surgery, combined mitral and aortic valve surgery, and CABG associated with heart valve surgery. Propensity Score Matching (PSM) was used to adjust for inequality in patients' preoperative characteristics before and after the implementation of QIP. A multivariate logistic regression model was built to predict hospital mortality and validated using discrimination and calibration metrics., Results: The PMS paired two groups using 5 variables, obtaining 858 patients operated before (non-QIP) and 858 patients operated after the implementation of the QIP. When comparing the QIP versus Non-QIP group, there was a shorter length of stay in all phases of hospitalization. In addition, the patients evolved with less anemia (P = 0.001), use of intra-aortic balloon pump (P = 0.003), atrial fibrillation (P = 0.001), acute kidney injury (P < 0.001), cardiogenic shock (P = 0.011), sepsis (P = 0.046), and hospital mortality (P = 0.001). In the multiple model, among the predictors of hospital mortality, the lack of QIP increased the chances of mortality by 2.09 times., Conclusion: The implementation of a first CS QIP in Latin America was associated with a reduction in length of hospital stay, complications and mortality after the cardiac surgeries analyzed., Competing Interests: Declaration of competing interest None., (Copyright © 2022 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
29. Quantum Biochemistry and MM-PBSA Description of the ZIKV NS2B-NS3 Protease: Insights into the Binding Interactions beyond the Catalytic Triad Pocket.
- Author
-
de Paula Junior VF, van Tilburg MF, Morais PA, Júnior FFM, Lima EG, Oliveira VTDS, Guedes MIF, Caetano EWS, and Freire VN
- Subjects
- Molecular Dynamics Simulation, Peptide Hydrolases metabolism, Protease Inhibitors chemistry, Serine Endopeptidases metabolism, Succinates, Viral Nonstructural Proteins metabolism, Zika Virus metabolism, Zika Virus Infection
- Abstract
The Zika virus protease NS2B-NS3 has a binding site formed with the participation of a H51-D75-S135 triad presenting two forms, active and inactive. Studies suggest that the inactive conformation is a good target for the design of inhibitors. In this paper, we evaluated the co-crystallized structures of the protease with the inhibitors benzoic acid (5YOD) and benzimidazole-1-ylmethanol (5H4I). We applied a protocol consisting of two steps: first, classical molecular mechanics energy minimization followed by classical molecular dynamics were performed, obtaining stabilized molecular geometries; second, the optimized/relaxed geometries were used in quantum biochemistry and molecular mechanics/Poisson-Boltzmann surface area (MM-PBSA) calculations to estimate the ligand interactions with each amino acid residue of the binding pocket. We show that the quantum-level results identified essential residues for the stabilization of the 5YOD and 5H4I complexes after classical energy minimization, matching previously published experimental data. The same success, however, was not observed for the MM-PBSA simulations. The application of quantum biochemistry methods seems to be more promising for the design of novel inhibitors acting on NS2B-NS3.
- Published
- 2022
- Full Text
- View/download PDF
30. Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia.
- Author
-
Bainey KR, Fleg JL, Hochman JS, Kunichoff DF, Anthopolos R, Chernyavskiy AM, Demkow M, Lopez-Quijano JM, Escobedo J, Poh KK, Ramos RB, Lima EG, Schuchlenz H, Ali ZA, Stone GW, Maron DJ, O'Brien SM, Spertus JA, and Bangalore S
- Subjects
- Coronary Angiography, Humans, Ischemia complications, Risk Factors, Coronary Artery Disease complications, Coronary Artery Disease diagnosis, Coronary Artery Disease epidemiology, Myocardial Ischemia complications, Myocardial Ischemia epidemiology, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic epidemiology
- Abstract
Background: The ISCHEMIA-CKD (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease) trial found no advantage to an invasive strategy compared to conservative management in reducing all-cause death or myocardial infarction (D/MI). However, the prognostic influence of angiographic coronary artery disease (CAD) burden and ischemia severity remains unknown in this population. We compared the relative impact of CAD extent and severity of myocardial ischemia on D/MI in patients with advanced chronic kidney disease (CKD)., Methods: Participants randomized to invasive management with available data on coronary angiography and stress testing were included. Extent of CAD was defined by the number of major epicardial vessels with ≥50% diameter stenosis by quantitative coronary angiography. Ischemia severity was assessed by site investigators as moderate or severe using trial definitions. The primary endpoint was D/MI., Results: Of the 388 participants, 307 (79.1%) had complete coronary angiography and stress testing data. D/MI occurred in 104/307 participants (33.9%). Extent of CAD was associated with an increased risk of D/MI (P < .001), while ischemia severity was not (P = .249). These relationships persisted following multivariable adjustment. Using 0-vessel disease (VD) as reference, the adjusted hazard ratio (HR) for 1VD was 1.86, 95% confidence interval (CI) 0.94 to 3.68, P = .073; 2VD: HR 2.13, 95% CI 1.10 to 4.12, P = .025; 3VD: HR 4.00, 95% CI 2.06 to 7.76, P < .001. Using moderate ischemia as the reference, the HR for severe ischemia was 0.84, 95% CI 0.54 to 1.30, P = .427., Conclusion: Among ISCHEMIA-CKD participants randomized to the invasive strategy, extent of CAD predicted D/MI whereas severity of ischemia did not., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. Surgical and percutaneous revascularization outcomes based on SYNTAX I, II, and residual scores: a long-term follow-up study.
- Author
-
Martins EB, Hueb W, Brown DL, Scudeler TL, Lima EG, Rezende PC, Soares PR, Garzillo CL, Filho JPPL, Batista DV, Ramires JAF, and Filho RK
- Subjects
- Coronary Artery Bypass, Follow-Up Studies, Humans, Retrospective Studies, Treatment Outcome, Coronary Artery Disease surgery, Percutaneous Coronary Intervention
- Abstract
Background: The objective of this study was to evaluate the association of SYNTAX scores I, II, and residual with cardiovascular outcomes of patients undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) and compare both procedures in a long-term follow-up., Methods: This is a retrospective single-center study from the MASS registry at the Heart Institute of the University of São Paulo, Brazil in which 969 patients with stable coronary artery disease undergoing CABG (559) or PCI (410) were included. We assessed the SYNTAX scores I, II and residual in both interventions. Clinical endpoints were the first occurrence of a composite of overall death, myocardial infarction, stroke, or repeat revascularization (MACCE) and the total occurrence of each component of MACCE., Results: In the CABG sample, SSI had a median of 23 (IQR 17-29.5), median SSII of 25.4 (IQR 19.2-32.8), and median rSS of 2 (IQR 0-6.5); in PCI SSI had a median of 14 (IQR 10-19.1), median SSII of 28.7 (IQR 23-34.2), and median rSS of 4.7 (IQR 0-9). Total of 174 events were documented and CABG patients had a lower rate of MACCE (15.6% vs. 21.2%; adjusted HR 1.98; 95% CI 1.13-3.47; P = 0.016) and repeat revascularization (3.8% vs. 11.5%; adjusted HR 4.35; CI 95% 1.74-10.85; P = 0.002) compared with PCI. No SYNTAX score tertile found a difference in death rate between procedures. In a multivariate analysis, the rSS was an independent predictor for MACCE (HR 1.04; 95% CI 1.01-1.06; P = 0.001). Regarding death, the only independent predictors were ejection fraction and renal function., Conclusion: Surgical revascularization resulted in a more complete revascularization and lower rates of major cardiac or cerebrovascular events in a long-term follow-up. Also, grading the incompleteness of revascularization through the residual SYNTAX score identified a higher event rate, suggesting that complete revascularization is associated with a better prognosis., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
32. Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up.
- Author
-
Batista DV, Hueb W, Lima EG, Rezende PC, Garzillo CL, Garcia RMR, Filho JPPL, Martins EB, Junior CVS, Ramires JAF, and Filho RK
- Subjects
- Aged, Aspirin administration & dosage, Calcium Channel Blockers administration & dosage, Coronary Artery Disease etiology, Coronary Artery Disease mortality, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Diabetic Nephropathies physiopathology, Female, Follow-Up Studies, Humans, Kidney Function Tests, Male, Middle Aged, Nitrates administration & dosage, Prospective Studies, Retrospective Studies, Coronary Artery Disease drug therapy, Diabetic Nephropathies complications
- Abstract
Background: The best treatment for coronary artery disease (CAD) in patients with type 2 diabetes (DM2) and chronic kidney disease is unknown., Methods: This retrospective study included MASS registry patients with DM2 and multivessel CAD, stratified by kidney function. Primary endpoint was combined of mortality, myocardial infarction, or additional revascularization., Results: Median follow-up was 9.5 years. Primary endpoint occurrences among strata 1 and 2 were 53.4% and 40.7%, respectively (P=.020). Mortality rates were 37.4% and 24.6% in strata 1 and 2, respectively (P<.001). We observed a lower rate of major adverse cardiovascular events (MACE) (P=.027 for stratum 1 and P<.001 for stratum 2) and additional revascularization (P=.001 for stratum 1 and P<.001 for stratum 2) for those in the surgical group. In a multivariate analysis, eGFR was an independent predictor of MACE (P=.034) and mortality (P=.020)., Conclusions: Among subjects with DM2 and CAD the presence of lower eGFR rate was associated with higher rates of MACE and mortality, irrespective of treatment choice. CABG was associated with lower rates of MACE in both renal function strata. eGFR was an independent predictor of MACE and mortality in a 10-year follow-up.
- Published
- 2021
- Full Text
- View/download PDF
33. Most deaths in low-risk cardiac surgery could be avoidable.
- Author
-
Mejia OAV, Borgomoni GB, Lima EG, Guerreiro GP, Dallan LR, de Barros E Silva P, Nakazone MA, Junior OP, Gomes WJ, de Oliveira MAP, Sousa A, Campagnucci VP, Tiveron MG, Rodrigues AJ, Tineli RÂ, Rocha E Silva R, Lisboa LAF, and Jatene FB
- Subjects
- Aged, Aged, 80 and over, Brazil epidemiology, Cardiac Surgical Procedures adverse effects, Cause of Death, Female, Humans, Male, Middle Aged, Patient Safety, Registries, Risk Factors, Survival Analysis, Cardiac Surgical Procedures mortality
- Abstract
It is observed that death rates in cardiac surgery has decreased, however, root causes that behave like triggers of potentially avoidable deaths (AD), especially in low-risk patients (less bias) are often unknown and underexplored, Phase of Care Mortality Analysis (POCMA) can be a valuable tool to identify seminal events (SE), providing valuable information where it is possible to make improvements in the quality and safety of future procedures. Our results show that in São Paul State, only one third of AD in low-risk cardiac surgery was related to specific surgical problems. After a revisited analysis, 75% of deaths could have been avoided, which in the pre-operative phase, the SE was related judgment, patient evaluation and preparation. In the intra-operative phase, most occurrences could have been avoided if other surgical technique had been used. Sepsis was responsible for 75% of AD in the intensive care unit. In the ward phase, the recognition/management of clinical decompensations and sepsis were the contributing factors. Logistic regression model identified age, previous coronary stent implantation, coronary artery bypass grafting + heart valve surgery, ≥ 2 combined heart valve surgery and hospital-acquired infection as independent predictors of AD.
- Published
- 2021
- Full Text
- View/download PDF
34. Occurrence of recently diagnosed atrial fibrillation in the immediate postoperative period of myocardial revascularization surgery. Although common, a devalued complication.
- Author
-
Pereira MP, Lima EG, Garzillo CL, Barbosa CTM, Sampaio LPC, Darrieux FCDC, and Serrano CV Jr
- Subjects
- Coronary Artery Bypass adverse effects, Humans, Postoperative Complications, Postoperative Period, Atrial Fibrillation epidemiology, Atrial Fibrillation etiology, Cardiac Surgical Procedures
- Abstract
Atrial fibrillation (AF) is the most common arrhythmia in the postoperative period of cardiac surgery, with a prevalence between 15-40% after coronary artery bypass surgery (CABG). Several strategies have been tested for the prevention and management of AF postoperatively. Previous studies and analysis of records have shown higher rates of hospitalization and clinical outcomes associated with this entity, including increased mortality in the short- and long-term. This perspective reviews the topic, and offers recommendations for the management of this arrhythmia in the postoperative period of CABG, with a special focus on anticoagulation strategies.
- Published
- 2020
- Full Text
- View/download PDF
35. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report.
- Author
-
Batista DV, Vieira CAFA, Costa TA, and Lima EG
- Abstract
Type 2 diabetes mellitus (DM) patients are at high risk for the development of severe COVID-19. Euglycemic diabetic ketoacidosis (eu-DKA) is a rare life-threatening complication associated with the use of SGLT2 inhibitor that may be unnoticed, particularly in a pandemic setting, due to the absence of significant hyperglycemia, delaying its treatment. In this report, we describe a case of a 56-year-old patient who presented an elevated anion gap metabolic acidosis during a SARS-CoV-2 infection and was diagnosed with SGLT2-associated euglycemic diabetic ketoacidosis. COVID-19 may increase patients' insulin demand, present gastrointestinal symptoms, and increase the production of ketone bodies. This situation can be worsened in susceptible diabetic patients on SLGT2 inhibitors, due to the persistent glycosuria, which can cause volume depletion. Recently some authors recommended that insulin-deficient patients or those using SGLT2 inhibitors should monitor for ketosis using available home testing kits in case of infections and should discontinue the medication in case of COVID-19. Given the increased use of this drug class in the management of type 2 DM patients due to its reduction of cardiovascular risk, we set out to emphasize the importance for the medical community to consider the possibility of eu-DKA on SARS-CoV-2-infected patients using SLGT2 inhibitors, so physicians can provide these patients with appropriate therapy promptly., Competing Interests: Conflict of interestThe authors have no conflicts of interests to disclose., (© The Japan Diabetes Society 2020.)
- Published
- 2020
- Full Text
- View/download PDF
36. Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes.
- Author
-
Martins EB, Lima EG, Pitta FG, Carvalho LNS, Queiroz TD, and Serrano Júnior CV
- Subjects
- Humans, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy
- Abstract
The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits: SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.
- Published
- 2020
- Full Text
- View/download PDF
37. Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) - 2020.
- Author
-
Soeiro AM, Leal TCAT, Pereira MP, Lima EG, Figueiredo ACBDS, Petriz JLF, Precoma DB, and Serrano CV Jr
- Subjects
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2, Anticoagulants therapeutic use, Coronavirus Infections drug therapy, Platelet Aggregation Inhibitors therapeutic use, Pneumonia, Viral drug therapy
- Published
- 2020
- Full Text
- View/download PDF
38. Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial.
- Author
-
Lima EG, Charytan DM, Hueb W, de Azevedo DFC, Garzillo CL, Favarato D, Linhares Filho JPP, Martins EB, Batista DV, Rezende PC, Hueb AC, Ramires JAF, and Kalil Filho R
- Subjects
- Aged, Coronary Artery Disease pathology, Coronary Artery Disease surgery, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Male, Middle Aged, Renal Insufficiency, Chronic pathology, Renal Insufficiency, Chronic surgery, Survival Rate, Time Factors, Treatment Outcome, Angioplasty mortality, Coronary Artery Bypass mortality, Coronary Artery Disease mortality, Percutaneous Coronary Intervention mortality, Renal Insufficiency, Chronic mortality
- Abstract
Background: Chronic kidney disease (CKD) is associated with a worse prognosis in patients with stable coronary artery disease (CAD); however, there is limited randomized data on long-term outcomes of CAD therapies in these patients. We evaluated long-term outcomes of CKD patients with CAD who underwent randomized therapy with medical treatment (MT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)., Methods: Baseline estimated glomerular filtration rate (eGFR) was obtained in 611 patients randomized to one of three therapeutic strategies in the Medicine, Angioplasty, or Surgery Study II trial. Patients were categorized in preserved renal function and mild or moderate CKD groups depending on their eGFR (≥90, 89-60 and 59-30 mL/min/1.73 m2, respectively). The primary clinical endpoint, a composite of overall death and myocardial infarction, and its individual components were analyzed using proportional hazards regression (Clinical Trial registration information: http://www.controlled-trials.com. Registration number: ISRCTN66068876)., Results: Of 611 patients, 112 (18%) had preserved eGFR, 349 (57%) mild dysfunction and 150 (25%) moderate dysfunction. The primary endpoint occurred in 29.5, 32.4 and 44.7% (P = 0.02) for preserved eGFR, mild CKD and moderate CKD, respectively. Overall mortality incidence was 18.7, 23.8 and 39.3% for preserved eGFR, mild CKD and moderate CKD, respectively (P = 0.001). For preserved eGFR, there was no significant difference in outcomes between therapies. For mild CKD, the primary event rate was 29.4% for PCI, 29.1% for CABG and 41.1% for MT (P = 0.006) [adjusted hazard ratio (HR) = 0.26, 95% confidence interval (CI) 0.07-0.88; P = 0.03 for PCI versus MT; and adjusted HR = 0.48; 95% CI 0.31-0.76; P = 0.002 for CABG versus MT]. We also observed higher mortality rates in the MT group (28.6%) compared with PCI (24.1%) and CABG (19.0%) groups (P = 0.015) among mild CKD subjects (adjusted HR = 0.44, 95% CI 0.25-0.76; P = 0.003 for CABG versus MT; adjusted HR = 0.56, 95% CI 0.07-4.28; P = 0.58 for PCI versus MT). Results were similar with moderate CKD group but did not achieve significance., Conclusions: Coronary interventional therapy, both PCI and CABG, is associated with lower rates of events compared with MT in mild CKD patients >10 years of follow-up. More study is needed to confirm these benefits in moderate CKD., (© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
39. Hypotheses, rationale, design, and methods for prognostic evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy who undergo medical or surgical treatment: MASS-VI (HF).
- Author
-
Rezende PC, Hueb W, Bocchi EA, Farkouh M, Junior CVS, Lima EG, Silva EER, Dallan LAO, Gaiotto FA, Garzillo CL, Rochitte CE, Nomura CH, Scudeler TL, Soares PR, Jatene FB, Ramires JAF, and Filho RK
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Coronary Artery Disease drug therapy, Coronary Artery Disease mortality, Cost-Benefit Analysis, Diuretics therapeutic use, Follow-Up Studies, Heart Failure etiology, Heart Failure surgery, Humans, Myocardial Ischemia drug therapy, Myocardial Ischemia mortality, Prognosis, Prospective Studies, Randomized Controlled Trials as Topic, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left drug therapy, Ventricular Dysfunction, Left mortality, Coronary Artery Bypass methods, Coronary Artery Disease complications, Coronary Artery Disease surgery, Myocardial Ischemia complications, Myocardial Ischemia surgery, Ventricular Dysfunction, Left complications, Ventricular Dysfunction, Left surgery
- Abstract
Background: Ischemic cardiomyopathy and severe left ventricular dysfunction are well established to represent the main determinants of poor survival and premature death compared with preserved ventricular function. However, the role of myocardial revascularization as a therapeutic alternative is not known to improve the long-term prognosis in this group of patients. This study will investigate whether myocardial revascularization contributes to a better prognosis for patients compared with those treated with drugs alone and followed over the long term., Methods: The study will include 600 patients with coronary artery disease associated with ischemic cardiomyopathy. The surgical or drug therapy option will be randomized, and the events considered for analysis will be all-cause mortality, nonfatal infarction, unstable angina requiring additional revascularization, and stroke. The events will be analyzed according to the intent-to-treat principle. Patients with multivessel coronary disease and left ventricular ejection fraction measurements of less than 35% will be included. In addition, myocardial ischemia will be documented by myocardial scintigraphy. Markers of myocardial necrosis will be checked at admission and after the procedure., Discussion: The role of myocardial revascularization (CABG) in the treatment of patients with coronary artery disease and heart failure is not clearly established. The surgical option of revascularizing the myocardium is a procedure designed to reduce the load of myocardial hibernation in patients with heart failure caused by coronary artery disease. On the other hand, the assessment of myocardial viability is frequently used to identify patients with left ventricular ischemic dysfunction in which CABG may add survival benefit. However, the effectiveness of this option is uncertain. The great difficulty in establishing the efficacy of surgical intervention is based on the understanding of viability without ischemia. Thus, this study will include only patients with viable and truly ischemic myocardium to correct this anomaly., Trial Registration: Evaluation of a randomized comparison between patients with coronary artery disease associated with ischemic cardiomyopathy submitted to medical or surgical treatment: MASS-VI (HF), ISRCTN77449548, Oct 10th, 2019 (retrospectively registered).
- Published
- 2020
- Full Text
- View/download PDF
40. Viral infections and atherothrombosis: Another caution in the wake of COVID-19?
- Author
-
Pereira MP, Lima EG, and Serrano Junior CV
- Subjects
- Acute Disease, Atherosclerosis physiopathology, COVID-19, Coronavirus Infections physiopathology, Humans, Pneumonia, Viral physiopathology, Prognosis, SARS-CoV-2, Thrombosis physiopathology, Atherosclerosis virology, Betacoronavirus, Coronavirus Infections complications, Pandemics, Pneumonia, Viral complications, Thrombosis virology
- Published
- 2020
- Full Text
- View/download PDF
41. Significant association of SYNTAX score on release of cardiac biomarkers in uncomplicated post-revascularization procedures among patients with stable multivessel disease: MASS-V Study group.
- Author
-
de Azevedo DFC, Hueb W, Lima EG, Rezende PC, Linhares Filho JPP, de Carvalho GF, Martins EB, Nomura CH, Strunz CMC, Serrano Junior CV, Ramires JAF, and Kalil Filho R
- Subjects
- Aged, Angioplasty methods, Atherosclerosis metabolism, Atherosclerosis pathology, Cardiac Surgical Procedures methods, Coronary Angiography trends, Coronary Artery Bypass methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease pathology, Female, Humans, Male, Middle Aged, Myocardial Infarction diagnosis, Myocardial Infarction metabolism, Myocardial Infarction therapy, Percutaneous Coronary Intervention methods, Prospective Studies, Troponin I metabolism, Biomarkers metabolism, Coronary Angiography methods, Coronary Artery Disease blood, Coronary Artery Disease surgery
- Abstract
This study investigated the relationship between angiographic complexities of coronary artery disease (CAD) assessed by SYNTAX Score synergy between percutaneous coronary intervention with taxus and cardiac surgery score (SYNTAX Score) and cardiac biomarker elevation after revascularization procedures.This is a post-hoc analysis of the medicine, angioplasty or surgery study V study of patients with stable CAD. High-sensitivity troponin 1 (hs-TnI) and creatinine kinase-muscle/brain (CK-MB) were assessed before and after cardiovascular procedures. Baselines SYNTAX Scores (SXScores) were calculated by blinded investigators to patient characteristics.Of the 202 patients studied, the mean SXScore was 21.25 ± 9.24; 40.10 ± 7.09 in the high SXScore group and 19.06 ± 6.61 in low/mid SXscore group (P < .0001). Positive correlations existed between SXScore and median peaks after procedural hs-TnI (r = 0.18, P = .009) and CK-MB (r = 0.24, P = .001) levels. In patients with high SXScores (≥33), the median peaks of post-procedural hs-TnI (P = .034)and CK-MB (P = .004) levels were higher than in low/mid SXScore group (<33).The release of hs-TnI at 6 (P = .002), 12 (P = .008), and 24 hours (P = .039) was higher in high SXScore group than in low/mid SXscore group (<33) as was the release of CK-MB at 6 (P < .0001), 12 (P < .0001), 24 (P = .001), 36 (P = .007), 48 (P = .008), and 72 hours (P = .023). After multivariable analysis, high SXScore was a significant independent predictor of release of CK-MB and hs-TnI peaks higher than the median.The increase in release of cardiac biomarkers was significantly associated with the extent of atherosclerosis identified by the SYNTAX Score.
- Published
- 2020
- Full Text
- View/download PDF
42. Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease.
- Author
-
Rezende PC, Hlatky MA, Hueb W, Garcia RMR, da Silva Selistre L, Lima EG, Garzillo CL, Scudeler TL, Boros GAB, Ribas FF, Serrano CV Jr, Ramires JAF, and Kalil Filho R
- Subjects
- Aged, Brazil, Cohort Studies, Female, Humans, Longitudinal Studies, Male, Middle Aged, Proportional Hazards Models, Risk Factors, Blood Glucose analysis, Coronary Artery Disease blood, Coronary Artery Disease physiopathology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Glycated Hemoglobin analysis
- Abstract
Importance: Glycated hemoglobin (HbA1c) values are used to guide glycemic control, but in patients with type 2 diabetes and multivessel coronary artery disease (CAD), the association of the longitudinal values of HbA1c with cardiovascular outcomes is unclear., Objective: To assess whether longitudinal variation of HbA1c is associated with cardiovascular events in long-term follow-up among patients with diabetes and multivessel CAD., Design, Setting, and Participants: This cohort study included 888 patients with type 2 diabetes and multivessel CAD in the Medicine, Angioplasty, or Surgery Study (MASS) Registry of the Heart Institute of the University of São Paulo from January 2003 to December 2007. Data were analyzed from January 15, 2018, to October 15, 2019., Exposure: Longitudinal HbA1c values., Main Outcomes and Measures: The combined outcome of all-cause mortality, myocardial infarction, and ischemic stroke., Results: Of 888 patients with type 2 diabetes and multivessel CAD, 725 (81.6%; median [range] age, 62.4 [55.7-68.0] years; 467 [64.4%] men) had complete clinical and HbA1c information during a median (interquartile range) follow-up period of 10.0 (8.0-12.3) years, with a mean (SD) of 9.5 (3.8) HbA1c values for each patient. The composite end point of death, myocardial infarction, or ischemic stroke occurred in 262 patients (36.1%). A 1-point increase in the longitudinal value of HbA1c was significantly associated with a 14% higher risk of the combined end point of all-cause mortality, myocardial infarction, and ischemic stroke (hazard ratio, 1.14; 95% CI, 1.04-1.24; P = .002) in the unadjusted analysis. After adjusting for baseline factors (ie, age, sex, 2-vessel or 3-vessel CAD, initial CAD treatments, ejection fraction, and creatinine and low-density lipoprotein cholesterol levels), a 1-point increase in the longitudinal value of HbA1c was associated with a 22% higher risk of the combined end point (hazard ratio, 1.22; 95% CI, 1.12-1.35; P < .001)., Conclusions and Relevance: Longitudinal increase of HbA1c was independently associated with higher rates of cardiovascular events in patients with type 2 diabetes and multivessel CAD.
- Published
- 2020
- Full Text
- View/download PDF
43. Atualização da Diretriz de Ressuscitação Cardiopulmonar e Cuidados Cardiovasculares de Emergência da Sociedade Brasileira de Cardiologia - 2019.
- Author
-
Bernoche C, Timerman S, Polastri TF, Giannetti NS, Siqueira AWDS, Piscopo A, Soeiro AM, Reis AGADC, Tanaka ACS, Thomaz AM, Quilici AP, Catarino AH, Ribeiro ACL, Barreto ACP, Azevedo Filho AFB, Pazin Filho A, Timerman A, Scarpa BR, Timerman B, Tavares CAM, Martins CSL, Serrano Junior CV, Malaque CMS, Pisani CF, Batista DV, Leandro DLF, Szpilman D, Gonçalves DM, Paiva EF, Osawa EA, Lima EG, Adam EL, Peixoto E, Evaristo EF, Azeka E, Silva FBD, Wen FH, Ferreira FG, Lima FG, Fernandes FL, Ganem F, Galas FRBG, Tarasoutchi F, Souza GEC, Feitosa Filho GS, Foronda G, Guimarães HP, Abud ICK, Leite ISL, Linhares Filho JPP, Moraes Junior JBMX, Falcão JLAA, Ramires JAF, Cavalini JF, Saraiva JFK, Abrão KC, Pinto LF, Bianchi LLT, Lopes LNGD, Piegas LS, Kopel L, Godoy LC, Tobase L, Hajjar LA, Dallan LAP, Caneo LF, Cardoso LF, Canesin MF, Park M, Rabelo MMN, Malachias MVB, Gonçalves MAB, Almeida MFB, Souza MFS, Favarato MHS, Carrion MJM, Gonzalez MM, Bortolotto MRFL, Macatrão-Costa MF, Shimoda MS, Oliveira-Junior MT, Ikari NM, Dutra OP, Berwanger O, Pinheiro PAPC, Reis PFFD, Cellia PHM, Santos Filho RDD, Gianotto-Oliveira R, Kalil Filho R, Guinsburg R, Managini S, Lage SHG, Yeu SP, Franchi SM, Shimoda-Sakano T, Accorsi TD, Leal TCA, Guimarães V, Sallai VS, Ávila WS, and Sako YK
- Subjects
- Brazil, Cardiology, Humans, Risk Assessment, Risk Factors, Societies, Medical standards, Treatment Outcome, Cardiopulmonary Resuscitation standards, Cardiovascular Diseases diagnosis, Cardiovascular Diseases therapy, Emergency Medical Services standards
- Published
- 2019
- Full Text
- View/download PDF
44. Association Between Stress Testing-Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease.
- Author
-
Garzillo CL, Hueb W, Gersh B, Rezende PC, Lima EG, Favarato D, Franchini Ramires JA, and Kalil Filho R
- Abstract
Importance: The long-term prognostic implications of myocardial ischemia documented during stress testing in patients with multivessel coronary artery disease (CAD) are unclear., Objective: To assess whether documented stress testing-induced myocardial ischemia is associated with major adverse cardiovascular events or ventricular function changes in patients with stable multivessel CAD., Design, Setting, and Participants: A prospective cohort study was conducted using data from a single-center randomized clinical trial (Medicine, Angioplasty, or Surgery Study [MASS] II) to examine the association of myocardial ischemia documented during stress testing at baseline with cardiovascular events and ventricular function changes during follow-up. Participants were previously randomized (May 1, 1995, to May 31, 2000) to medical therapy, percutaneous coronary intervention with bare metal stents, or coronary artery bypass grafting. Event-free survival was estimated by the Kaplan-Meier method, and multivariable Cox regression models were calculated to assess the association between ischemia and the primary composite end point. The vital status was determined on February 28, 2011. Data were analyzed from February 1, 2016, to April 1, 2017., Main Outcomes and Measures: Cardiovascular events (overall mortality, myocardial infarction, and revascularization for refractory angina) were tracked from the time of randomization to the end of the 10-year follow-up (mean [SD] duration, 11.4 [4.3] years). Myocardial ischemia was assessed at baseline and at 1-year intervals by exercise stress testing, and ventricular function (left ventricular ejection fraction) was assessed by echocardiography at baseline and after 10 years. Patients with documented ischemia were compared with those without ischemia regarding the outcomes and changes in ventricular function., Results: Of 611 participants, 535 underwent exercise stress testing at baseline: 270 with documented ischemia and 265 without. Of these 535 patients, 373 (69.7%) were men, and the mean (SD) age for the entire cohort was 59.7 (9.2) years. No association was found between the presence of ischemia at baseline and survival free of combined cardiovascular events (hazard ratio, 1.00; 95% CI, 0.80-1.27; P = .95) after multivariable adjustment that included CAD initial randomized treatments. In addition, among 320 patients who underwent echocardiographic evaluation, the slight decline in left ventricular ejection fraction after 10 years was similar in both groups (median [SD] difference, -4.9% [18.7%] vs -6.6% [20.0%], respectively, for groups with and without ischemia; P = .97)., Conclusions and Relevance: In this study, regardless of the therapeutic strategy applied, the presence of documented myocardial ischemia did not appear to be associated with an increased occurrence of major adverse cardiovascular events or changes in ventricular function in patients with multivessel CAD during a long-term follow-up.
- Published
- 2019
- Full Text
- View/download PDF
45. Ten-Year Follow-Up of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Grafting: MASS III.
- Author
-
Hueb W, Rezende PC, Gersh BJ, Soares PR, Favarato D, Lima EG, Garzillo CL, Jatene FB, Ramires JAF, and Filho RK
- Subjects
- Aged, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Stenosis diagnostic imaging, Coronary Stenosis mortality, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Postoperative Complications mortality, Postoperative Complications therapy, Progression-Free Survival, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Cardiopulmonary Bypass adverse effects, Cardiopulmonary Bypass mortality, Coronary Artery Bypass adverse effects, Coronary Artery Bypass mortality, Coronary Artery Bypass, Off-Pump adverse effects, Coronary Artery Bypass, Off-Pump mortality, Coronary Artery Disease surgery, Coronary Stenosis surgery
- Abstract
It was a randomized trial, and 308 patients undergoing revascularization were randomly assigned: 155 to off-pump coronary artery bypass (OPCAB) and 153 to on-pump coronary artery bypass (ONCAB). End points were freedom from death, myocardial infarction, revascularization, and cerebrovascular accidents. The rates for 10-year, event-free survival for ONCAB versus OPCAB were 69.6% and 64%, (hazard ratio [HR]: 0.88; 95% confidence interval [CI] 0.86-1.02; P = .41), respectively. Adjusted Cox proportional hazard ratio was similar (HR: 0.92; 95% CI 0.61-1.38, P = .68). A difference occurred between the duration of OPCAB and ONCAB, respectively (4.9 ± 1.5 vs 6.6 ± 1.1 h, P < .001). Statistical differences occurred between OPCAB and ONCAB in the length of intensive care unit (ICU) stay (20 ± 2.5 vs 48 ± 10 hours, P < .001), time to extubation (5.5 ± 4.2 vs 10.2 ± 3.5 hours, P < .001), hospital stay (6.7 ± 1.4 vs 9.2 ± 1.3 days, P < .001), higher incidence of atrial fibrillation (AF; 33 vs 5 patients, P < .001), and blood requirements (46 vs 64 patients, P < .001). Grafts per patient was higher in ONCAB (3.15 vs 2.55 grafts, P < .001). No difference existed between the groups in primary composite end points at 10-year follow-up. Although OPCAB surgery was related to a lower number of grafts and higher incidence of AF, it had no effects related to long-term outcomes.
- Published
- 2019
- Full Text
- View/download PDF
46. Effect of chronic kidney disease in ischemic cardiomyopathy: Long-term follow-up - REVISION-DM2 trial.
- Author
-
Hueb TO, Lima EG, Rocha MS, Siqueira SF, Nishioka SAD, Peixoto GL, Saccab MM, Garcia RMR, Ramires JAF, Kalil Filho R, and Martinelli Filho M
- Subjects
- Aged, Cardiovascular Agents therapeutic use, Coronary Artery Disease mortality, Coronary Artery Disease therapy, Follow-Up Studies, Heart Function Tests, Humans, Kaplan-Meier Estimate, Kidney Function Tests, Middle Aged, Percutaneous Coronary Intervention methods, Reoperation statistics & numerical data, Smoking epidemiology, Socioeconomic Factors, Coronary Artery Disease epidemiology, Coronary Artery Disease physiopathology, Renal Insufficiency, Chronic epidemiology, Renal Insufficiency, Chronic physiopathology
- Abstract
A strong association exists between chronic kidney disease (CKD) and coronary artery disease (CAD). The role of CKD in the long-term prognosis of CAD patients with versus those without CKD is unknown. This study investigated whether CKD affects ventricular function.From January 2009 to January 2010, 918 consecutive patients were selected from an outpatient database. Patients had undergone percutaneous, surgical, or clinical treatment and were followed until May 2015.In patients with preserved renal function (n = 405), 73 events (18%) occurred, but 108 events (21.1%) occurred among those with CKD (n = 513) (P < .001). Regarding left ventricular ejection fraction (LVEF) <50%, we found 84 events (21.5%) in CKD patients and 12 (11.8%) in those with preserved renal function (P < .001). The presence of LVEF <50% brought about a modification effect. Death occurred in 22 (5.4%) patients with preserved renal function and in 73 (14.2%) with CKD (P < .001). In subjects with LVEF <50%, 66 deaths (16.9%) occurred in CKD patients and 7 (6.9%) in those with preserved renal function (P = .001). No differences were found in CKD strata regarding events or overall death among those with preserved LVEF. In a multivariate model, creatinine clearance remained an independent predictor of death (P < .001).We found no deleterious effects of CKD in patients with CAD when ventricular function was preserved. However, there was a worse prognosis in patients with CKD and ventricular dysfunction.Resgistry number is ISRCTN17786790 at https://doi.org/10.1186/ISRCTN17786790.
- Published
- 2019
- Full Text
- View/download PDF
47. Dual platelet antiaggregation therapy after myocardial revascularization surgery.
- Author
-
Feitosa MPM, Soffiatti CD, Linhares Filho JPP, Batista DV, Lobo Filho HG, Lima EG, and Serrano Júnior CV
- Subjects
- Aspirin therapeutic use, Clopidogrel therapeutic use, Coronary Artery Bypass adverse effects, Coronary Artery Disease surgery, Humans, Ticagrelor therapeutic use, Treatment Outcome, Coronary Artery Bypass methods, Graft Occlusion, Vascular prevention & control, Platelet Aggregation Inhibitors therapeutic use, Vascular Patency drug effects
- Abstract
Coronary artery bypass graft (CABG) is a consolidated treatment in patients with coronary artery disease (CAD) for both symptom control and improvement of prognosis. The patency of venous grafts is still the most vulnerable point of the surgical treatment since it presents a high prevalence of occlusion both in the immediate postoperative period and in the long-term follow-up. Aspirin plays a well-established role in this setting, and for a long time, clopidogrel use has been restricted to patients allergic to aspirin. Recently, subgroup analyses of studies with different anti-platelet therapies have shown reduced mortality and cardiovascular events in patients on dual anti-platelet antiplatelet therapy (DAPT) undergoing CABG, although such studies have not been designed to evaluate this patient profile. However, there is still an insufficient number of randomized studies using DAPT in this context, resulting in a disagreement between the European and American cardiology societies guidelines regarding their indication and generating doubts in clinical practice.
- Published
- 2019
- Full Text
- View/download PDF
48. Critical analysis of the classic indications for myocardial revascularization.
- Author
-
Azevedo DFC, Lima EG, Ribeiro MOL, Linhares Filho JPP, and Serrano Júnior CV
- Subjects
- Clinical Decision-Making, Humans, Myocardial Revascularization methods, Prognosis, Risk Assessment, Risk Factors, Coronary Artery Disease surgery, Myocardial Revascularization standards
- Abstract
Treatment of stable coronary artery disease (CAD) relies on improved prognosis and relief of symptoms. National and international guidelines on CAD support the indication of revascularization in patients with limiting symptoms and refractory to optimal medical treatment, as well as in clinical situations where there is a prognostic benefit of interventional treatment. Most of the studies that support the guidelines for indication of revascularization date back to the 1980s and1990s of the last century. Recent studies have revisited the theme and brought a new breath. The present review provides a critical analysis of classic indications for revascularization, reviewing evidence from the studies of the 1970s to the recent controversial ORBITA study.
- Published
- 2019
- Full Text
- View/download PDF
49. Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial.
- Author
-
Scudeler TL, Hueb WA, Farkouh ME, Maron DJ, de Soárez PC, Campolina AG, Takiuti ME, Rezende PC, Godoy LC, Hueb AC, Lima EG, Garzillo CL, Ramires JAF, and Kalil Filho R
- Subjects
- Brazil epidemiology, Coronary Artery Bypass trends, Coronary Artery Bypass, Off-Pump trends, Coronary Artery Disease epidemiology, Cost-Benefit Analysis trends, Female, Follow-Up Studies, Humans, Male, Markov Chains, Coronary Artery Bypass economics, Coronary Artery Bypass, Off-Pump economics, Coronary Artery Disease economics, Coronary Artery Disease surgery, Cost-Benefit Analysis methods
- Abstract
Background: Recent trials have reported similar clinical outcomes between on-pump and off-pump coronary artery bypass graft (CABG). However, long-term cost-effectiveness of these strategies is unknown., Methods: A prespecified economic study was performed based on the MASS III trial. Costs were estimated for all patients based on observed healthcare resource usage over a 5-year follow-up. Health state utilities were evaluated with the SF-6D questionnaire. Cost-effectiveness was assessed as cost per quality-adjusted life-year (QALY) gained using a Markov model. Probabilistic sensitivity analysis with the Monte-Carlo simulation and cost-effectiveness acceptability curve were used to address uncertainty., Results: Quality of life improved significantly in both groups during follow-up compared with baseline. At 5 years, when comparing on-pump and off-pump CABG groups, no differences were found in cumulative life-years (4.851 and 4.766 years, P = .319) and QALY gained (4.150 and 4.105 QALYs, P = .332). Mean cost in US dollars per patient during the trial did not differ significantly between the on-pump and off-pump groups ($5890.29 and $5674.75, respectively, P = .409). Over a lifetime horizon, the incremental cost-effectiveness ratio of on-pump versus off-pump CABG was $12,576 per QALY gained, which is above the suggested cost-effectiveness threshold range (from $3210 to 10,122). In the sensitivity analysis, the probability that on-pump CABG is cost-effective compared to off-pump surgery for a willingness-to-pay threshold of $3212 per QALY gained was <1%. For the $10,122 per QALY threshold, the same probability was 35%., Conclusion: This decision-analytic model suggests that on-pump CABG is not cost-effective when compared to off-pump CABG from a public health system perspective., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
50. CULPRIT-SHOCK study.
- Author
-
Souza Júnior JM, Kulchetscki RM, Linhares Filho JPP, Lima EG, and Serrano Junior CV
- Subjects
- Acute Coronary Syndrome complications, Coronary Artery Disease complications, Europe, Humans, Myocardial Revascularization methods, Practice Guidelines as Topic, ST Elevation Myocardial Infarction complications, Shock, Cardiogenic etiology, Treatment Outcome, Acute Coronary Syndrome surgery, Coronary Artery Disease surgery, Percutaneous Coronary Intervention methods, Randomized Controlled Trials as Topic, ST Elevation Myocardial Infarction surgery, Shock, Cardiogenic surgery
- Abstract
The treatment of patients with ST-segment elevation myocardial infarction concomitant with the presence of multivessel disease has been studied in several recent studies with the purpose of defining the need, as well as the best moment to approach residual lesions. However, such studies included only stable patients. The best therapeutic approach to cardiogenic shock secondary to acute coronary syndrome, however, remains controversial, but there are recommendations from specialists for revascularization that include non-event related injuries. Recently published, the CULPRIT-SHOCK study showed benefit of the initial approach only of the injury blamed for the acute event, in view of the multivessel percutaneous intervention, in the context of cardiogenic shock. In this perspective, the authors discuss the work in question, regarding methodological questions, limitations and clinical applicability.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.